The Modified Ottawa Score and Clinical Events in Hospitalized Patients with Cancer-Associated Thrombosis from the Swiss VTE Registry

被引：17

作者：

Alatri, Adriano ^{[1
]}

Mazzolai, Lucia ^{[1
]}

Kucher, Nils ^{[2
]}

Aujesky, Drahomir ^{[3
]}

Beer, Juerg H. ^{[4
]}

Baldi, Thomas ^{[5
]}

Banyai, Martin ^{[6
]}

Hayoz, Daniel ^{[7
]}

Kaeslin, Thomas ^{[8
]}

Korte, Wolfgang ^{[9
]}

Escher, Robert ^{[10
]}

Husmann, Marc ^{[11
]}

Frauchiger, Beat ^{[12
]}

Engelberger, Rolf P. ^{[2
]}

Baumgartner, Iris ^{[2
]}

Spirk, David ^{[13
]}

机构：

[1] Lausanne Univ Hosp, Div Angiol, Lausanne, Switzerland

[2] Bern Univ Hosp, Swiss Cardiovasc Ctr, Div Vasc Med, Bern, Switzerland

[3] Bern Univ Hosp, Div Gen Internal Med, Bern, Switzerland

[4] Cantonal Hosp Baden, Dept Internal Med, Baden, Switzerland

[5] Univ Hosp Basel, Dept Internal Med, Basel, Switzerland

[6] Cantonal Hosp Lucerne, Dept Internal Med, Luzern, Switzerland

[7] Cantonal Hosp Fribourg, Dept Internal Med, Fribourg, Switzerland

[8] Cantonal Hosp Obwalden, Dept Internal Med, Sarnen, Switzerland

[9] Cantonal Hosp St Gallen, Dept Internal Med, St Gallen, Switzerland

[10] Reg Hosp Burgdorf, Dept Internal Med, Burgdorf, Switzerland

[11] Univ Hosp Zurich, Clin Angiol, Zurich, Switzerland

[12] Cantonal Hosp Frauenfeld, Dept Internal Med, Frauenfeld, Switzerland

[13] Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland

来源：

SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2017年 / 43卷 / 08期

关键词：

cancer; mortality; modified Ottawa score; venous thromboembolism; RECURRENT VENOUS THROMBOEMBOLISM; PREDICTION RULE; RISK; VALIDATION; GUIDELINE; THERAPY;

D O I：

10.1055/s-0037-1604086

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The modified Ottawa score (MOS) predicted venous thromboembolism (VTE) recurrence in a cohort of patients with cancer-associated thrombosis mainly managed on an outpatient basis. We aimed to assess the prognostic value of the MOS in hospitalized patients with cancer-associated thrombosis. In 383 hospitalized patients with cancer-associated VTE from the SWIss VTE Registry, 98 (25%) were classified as low risk, 175 (46%) as intermediate risk, and 110 (29%) as high risk for VTE recurrence based on the MOS. Clinical end points were recurrent VTE, fatal VTE, major bleeding, and overall mortality at 90 days. Overall, 179 (47%) patients were female, 172 (45%) had metastatic disease, and 72 (19%) prior VTE. The primary site of cancer was lung in 48 (13%) patients and breast in 43 (11%). According to the MOS, the rate of VTE recurrence was 4.1% for low, 6.3% intermediate, and 5.5% high risk ( p =0.75); the rate of fatal VTE was 0.8, 1.9, and 2.0% ( p =0.69); the rate of major bleeding was 3.1, 4.1, and 3.6% ( p =0.92); and the rate of death was 6.1, 12.0, and 28.2% ( p <0.001), respectively. None of the MOS items was associated with VTE recurrence: female gender hazard ratio (HR) 1.26 (95% confidence interval [CI], 0.53-2.96), lung cancer HR 1.17 (95% CI, 0.35-3.98), prior VTE HR 0.44 (95% CI, 0.10-1.91), breast cancer HR 0.83 (95% CI, 0.19-3.58), and absence of metastases HR 0.74 (95% CI, 0.31-1.74). In hospitalized patients with cancer-associated VTE, the MOS failed to predict VTE recurrence at 3 months but was associated with early mortality.

引用

页码：871 / 876

页数：6

共 18 条

[1] Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score [J].